Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JESSE COREY BOODOO

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1346689775
CMS profile
487281
Location
SARASOTA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2024 · Entire year

$4,329.99

148 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2024 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $3,608.95 144
Travel and Lodging $721.04 4

By paying entity

PY2024 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 148 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JESSE COREY BOODOO

NPI 1346689775 · CMS profile ID 487281

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

SARASOTA, FL

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 148 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1346689775?year=2024&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JESSE COREY BOODOO, NPI 1346689775, CMS profile ID 487281. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 148 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1346689775?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
APA 7
IndustryPayments. (2026). JESSE COREY BOODOO, NPI 1346689775, CMS profile ID 487281. General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 148 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1346689775?year=2024&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff.
Bluebook
JESSE COREY BOODOO, NPI 1346689775, CMS profile ID 487281, IndustryPayments, General Payments, PY2024; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 148 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/e6b17c6a-2534-4207-a4a1-6746a14911ff. https://industrypayments.org/provider/npi-1346689775?year=2024&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2024 · Physicians and non-physician practitioners · CMS publication 2026-06-30

148 matching records · $4,329.99 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 148 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 148.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $16.0308/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111533040 CMS
ABBVIE INC. $18.0308/07/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103347262 CMS
UCB, Inc. $29.6708/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143013816 CMS
Novartis Pharmaceuticals Corporation $24.4707/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086744713 CMS
ABBVIE INC. $28.5007/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103347260 CMS
Novartis Pharmaceuticals Corporation $13.5907/22/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086744711 CMS
Amgen Inc. $22.9107/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111533022 CMS
GlaxoSmithKline, LLC. $19.0607/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116415307 CMS
ABBVIE INC. $28.5907/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103347258 CMS
Novartis Pharmaceuticals Corporation $123.0307/13/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086744703 CMS
Novartis Pharmaceuticals Corporation $31.1907/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086744701 CMS
Novartis Pharmaceuticals Corporation $21.3607/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086744709 CMS
Almatica Pharma LLC $17.6507/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1137557713 CMS
GlaxoSmithKline, LLC. $15.1507/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116693737 CMS
Novartis Pharmaceuticals Corporation $30.2606/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086744699 CMS
Amgen Inc. $14.8806/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111533018 CMS
GlaxoSmithKline, LLC. $19.4606/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116639264 CMS
Novartis Pharmaceuticals Corporation $13.4106/27/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086744707 CMS
Amgen Inc. $27.3206/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111533026 CMS
Novartis Pharmaceuticals Corporation $18.1906/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086744705 CMS
Lilly USA, LLC $27.1206/05/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135045282 CMS
E.R. Squibb & Sons, L.L.C. $24.4606/03/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101311221 CMS
Amgen Inc. $24.1705/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111533016 CMS
E.R. Squibb & Sons, L.L.C. $115.1105/29/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101311225 CMS
AstraZeneca Pharmaceuticals LP $17.4905/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104655281 CMS
AstraZeneca Pharmaceuticals LP $18.5705/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1105688511 CMS
Genentech USA, Inc. $20.0405/21/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1133032058 CMS
ABBVIE INC. $28.5705/14/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103347256 CMS
ABBVIE INC. $24.0005/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103347254 CMS
GlaxoSmithKline, LLC. $19.9505/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116529514 CMS
UCB, Inc. $0.3205/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143013810 CMS
UCB, Inc. $0.4905/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143013812 CMS
UCB, Inc. $21.1305/06/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1143013814 CMS
Radius Health, Inc. $25.1505/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089960891 CMS
ABBVIE INC. $23.9804/30/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103347252 CMS
ABBVIE INC. $23.3504/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103347250 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $121.2304/25/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117974295 CMS
Janssen Biotech, Inc. $22.7504/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1078485462 CMS
Novartis Pharmaceuticals Corporation $23.2604/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086744695 CMS
Novartis Pharmaceuticals Corporation $0.7104/23/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086744697 CMS
Radius Health, Inc. $15.1504/18/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1089960887 CMS
Amgen Inc. $6.5004/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111533038 CMS
AstraZeneca Pharmaceuticals LP $19.9904/17/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1104719401 CMS
GlaxoSmithKline, LLC. $19.0004/16/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1116456409 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $15.8104/11/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1117974293 CMS
E.R. Squibb & Sons, L.L.C. $30.6304/10/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1101311203 CMS
Lilly USA, LLC $16.3004/09/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1135065437 CMS
Novartis Pharmaceuticals Corporation $15.9704/08/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1086744677 CMS
Amgen Inc. $18.5804/02/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1111533024 CMS
ABBVIE INC. $19.7203/28/2024 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1103347248 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,877.01 177
PY2020 $1,376.15 76
PY2021 $480.90 25
PY2022 $1,149.37 45
PY2023 $2,817.41 107
PY2024 $4,329.99 148
PY2025 $3,043.49 112

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $360,786.43 12
PY2024 Principal investigator $665,725.18 5
PY2023 Principal investigator $5,000.00 1

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

12 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Novartis Pharmaceuticals Corporation $488.40 12/08/2025 Non-covered Recipient Entity
WEITZNER YONKER KAINE
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup No dispute reported 06/30/2026 1190300587
Principal investigator 1 Novartis Pharmaceuticals Corporation $17.12 11/15/2025 Non-covered Recipient Entity
SARASOTA ARTHRITIS RESEARCH CENTER
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol No dispute reported 06/30/2026 1190303081
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,020.00 11/05/2025 Non-covered Recipient Entity
WEITZNER YONKER KAINE MD PA
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288075
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,040.00 11/05/2025 Non-covered Recipient Entity
WEITZNER YONKER KAINE MD PA
A Multi-Center, Randomized, Double-Blind, Placebo- and Active-Controlled Phase 3 Study to Evaluate the Efficacy and Safety of Zasocitinib (TAK-279) in Subjects With Active Psoriatic Arthritis Who Are Naive to Biologic Disease-Modifying Antirheumatic Drugs (LATITUDE-PsA-3001) No dispute reported 06/30/2026 1223288077
Principal investigator 1 Novartis Pharmaceuticals Corporation $157.50 10/08/2025 Non-covered Recipient Entity
SARASOTA ARTHRITIS RESEARCH CENTER
A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patien No dispute reported 06/30/2026 1190303087
Principal investigator 1 Novartis Pharmaceuticals Corporation $318.24 10/08/2025 Non-covered Recipient Entity
SARASOTA ARTHRITIS RESEARCH CENTER
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome No dispute reported 06/30/2026 1190303091
Principal investigator 1 Novartis Pharmaceuticals Corporation $494.92 07/09/2025 Non-covered Recipient Entity
SARASOTA ARTHRITIS RESEARCH CENTER
A randomized, double-blind 2-arm NEPTUNUS extension study to assess the long-term safety and efficacy of ianalumab in patients with Sjogrens syndrome No dispute reported 06/30/2026 1190303095
Principal investigator 1 Novartis Pharmaceuticals Corporation $44,479.52 02/10/2025 Non-covered Recipient Entity
SARASOTA ARTHRITIS RESEARCH CENTER
A Multi-center, Open-label Extension Study of Subcutaneous Secukinumab to Evaluate the Long-term Safety and Tolerability in Polymyalgia Rheumatica (PMR) No dispute reported 06/30/2026 1190303085
Principal investigator 1 Novartis Pharmaceuticals Corporation $943.46 02/01/2025 Non-covered Recipient Entity
WEITZNER YONKER KAINE
A randomized, double-blind, double-dummy, placebo-controlled, multicenter, Phase 3 study assessing the efficacy, safety, and tolerability of 2 doses of remibrutinib over a 68-week treatment period in adult patients with moderate to severe hidradenitis sup No dispute reported 06/30/2026 1190300589
Principal investigator 1 Novartis Pharmaceuticals Corporation $15,169.00 01/30/2025 Non-covered Recipient Entity
WEITZNER YONKER KAINE
A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patien No dispute reported 06/30/2026 1190300585
Principal investigator 1 Novartis Pharmaceuticals Corporation $23,061.95 01/10/2025 Non-covered Recipient Entity
SARASOTA ARTHRITIS RESEARCH CENTER
A Randomized, Parallel-group, Double-blind, Placebo-controlled, Multicenter Phase III Trial to Evaluate Efficacy and Safety of Secukinumab Administered Subcutaneously Versus Placebo, in Combination With a Glucocorticoid Taper Regimen, in Patients With Pol No dispute reported 06/30/2026 1190303083
Principal investigator 1 Novartis Pharmaceuticals Corporation $263,596.32 01/01/2025 Non-covered Recipient Entity
SARASOTA ARTHRITIS RESEARCH CENTER
A Randomized, Parallel Group, Double Blind, Placebo Controlled Multicenter Phase III Trial to Investigate the Efficacy and Safety of Secukinumab 300 mg Administered Subcutaneously Versus Placebo, in Combination With Glucocorticoid Taper Regimen, in Patien No dispute reported 06/30/2026 1190303089